Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA2001YUM" target="_blank" >RIV/61988987:17110/19:A2001YUM - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/19:E0107809

Výsledek na webu

<a href="https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1480766?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1480766?needAccess=true</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2018.1480766" target="_blank" >10.1080/10428194.2018.1480766</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Popis výsledku v původním jazyce

A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.

Název v anglickém jazyce

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Popis výsledku anglicky

A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia and Lymphoma

ISSN

1042-8194

e-ISSN

1029-2403

Svazek periodika

60

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

471-476

Kód UT WoS článku

000463555600025

EID výsledku v databázi Scopus

2-s2.0-85050555358